<DOC>
	<DOC>NCT01114893</DOC>
	<brief_summary>The purpose of this study is to determine the safety and efficacy of three concentrations of travoprost ophthalmic solution (Groups A, B and C) administered eight times daily.</brief_summary>
	<brief_title>Travoprost Five Day Posology Study</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<criteria>1. either sex and any race/ethnicity, ≥18 years old 2. diagnosed with openangle glaucoma, and/or ocular hypertension 3. meets the following IOP entry criteria: Mean IOP ≥ 24 millimeters mercury (mmHg) in at least 1 eye, with the same eye qualifying at 8 AM on both the Eligibility Visit (Day 0) and Day 1 Mean IOP ≤ 36 mmHg in both eyes at 8 AM and 8 PM at the Eligibility Visit (Day 0), and at 8 AM on Day 1 4. satisfies all informed consent requirements; able to read, sign and date the informed consent 1. females of childbearing potential not meeting protocol conditions 2. angle grade less than Grade 2 in either eye 3. cup to disc ratio greater than 0.8 (horizontal or vertical measurement) in either eye 4. severe central visual field loss in either eye 5. any abnormality preventing reliable applanation tonometry in either eye 6. hypersensitivity to prostaglandin analogues or to any component of the study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>